TechValidate Research on Elsevier PharmaPendium


Elsevier PharmaPendium Case Study

Teva is using PharmaPendium to inform drug candidate selection, improve clinical trial design and better understand safety risks

Introduction

This case study of Teva is based on a May 2017 survey of Elsevier PharmaPendium customers by TechValidate, a 3rd-party research service.

“PharmaPendium saved my team time.”

Challenges

The business challenges that led Teva to evaluate and ultimately select Elsevier PharmaPendium:

  • Reduce the number of preclinical studies that are required by citing relevant preclinical studies
  • Have more confidence in go/no-go drug development decisions/recommendations
  • Improve the speed and success of regulatory submissions

Use Case

  • Uses PharmaPendium weekly.
  • Teva has:
    • >5 drugs in the pipeline
    • A focus on generic drugs
    • An involvement in regulatory submissions
    • A focus on performing clinical trials on drugs in development

Results

Teva uses the data in PharmaPendium for their work in the following ways:

  • To better inform drug candidate selection by looking at comparative preclinical and clinical safety, deliverability and/or efficacy data
  • To design better clinical trials that will optimize benefit:risk ratio for their drug candidate
  • To better understand safety risks related to drug-drug interactions, off-target effects and/or polypharmacy
  • Teva would spend over 50% more time collecting the equivalent information without access to PharmaPendium.
  • Survey respondents recommend to continue subscribing to PharmaPendium.




About This Data

This data was sourced directly from verified users of Elsevier PharmaPendium by TechValidate.

TechValidate verifies the identity and organizational affiliation of all participants that contribute to published research data. When research participants so desire, we also guarantee their anonymity so that they may share information honestly and freely.


More Research on Elsevier PharmaPendium